BAGSVAERD, DENMARK -- (Marketwire) -- 02/02/12 --
Sales growth of 9% driven by Victoza®, NovoRapid® and Levemir®
Company Announcement no 7 / 2012: http://hugin.info/2013/R/1581997/494216.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
Tel: (+45) 4442 3573
In North America
Tel: (+1) 609 786 8316
Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Frank Daniel Mersebach
Tel: (+45) 4442 0604
Lars Borup Jacobsen
Tel: (+45) 3075 3479
Tel: (+1) 609 786 4575
Further information about Novo Nordisk is available on the company's website
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here